OPIOID THERAPY

Request Form FAX to 503-416-8109

Created: 01/25/18



315 SW Fifth Avenue, Suite 900 Portland, Oregon 97204 503-416-4100 or 800-224-4840 800-735-2900 (TTY/TDD) www.careoregon.org

For assistance with this form, you may call CareOregon at 503.416.4100 or 800.224.4840 - Monday through Friday from 8 am - 5 pm. CareOregon requests careful selection when checking urgent as it delays review of other requests that may seriously jeopardize the health of another member, please mark URGENT only as necessary. To view our drug policies, search through the PA Criteria Document.

** Incomplete requests may result in denials or delay to seek additional information**				
Both Standard and Urgent requests will be reviewed within 24 hours URGENT REQUEST Initial response within 24 hours (Should be reserved for those actively on treatment or in transplant setting)				
Patient Name:		Prescriber Name:		
Member ID #:		NPI#:		
Patient DOB:		Clinic Name:		
Pharmacy Name:		Prescriber Office Phone:	Prescriber Office Fax:	
Pharmacy Phone:		Prescriber Contact Person:		
Medication Requested (including strength and directions):				
Diagnoses (list all that apply including ICD10)				
Acute Use or Chronic?	☐ Acute with specified duration (define):		☐ Chronic (no planned end date)	
Planned Taper?	☐ No ☐ Yes (state taper plan goal and timeline):			
Past Opioid failures:				
Has the member the member actively participated in ☐ Yes ☐ No				
<u>non-medication modalities</u> Examples: Physical activity/exercise, acupuncture, yoga, group support classes				
Assessment of Risk/Abuse. Please attest to assessing risk/abuse via ALL the follow			Has the member demonstrated functional	
\square Risk of abuse (ORT, C	AGE-AID, SOPP-R, COMM, DIRI	E, ORS, and AUDIT)	improvement while on opioids?:	
☐ Risk of respiratory ad	verse events		☐ Yes ☐ No	
☐ Mental Health/Depre	ssion Screening		Examples include PEG, FRQ, and PDI	
(PHQ-9, GAD-7, PC-P1	SD or mental health evaluatio	n)	questionnaires. Alternatively:	
☐ Urine drug screen			documentation of changes from baseline	
□ PDMP Reviewed			functional status.	
Co-prescribing naloxone: Evidence has shown a significant reduction in overdose events when high risk opioids are co-prescribed with naloxone. Please document if any of the following high risk scenarios apply and if naloxone has been co-prescribed?				
High risk scenarios for opioid overdose (check all that apply):				
☐ Opioid dose ≥ 50 MED				
☐ Comorbid respiratory co	ndition (such as sleep apnea, o	COPD) Naloxone (Narcan	Naloxone (Narcan Nasal or injectable naloxone) Prescribed?	
☐ Concomitant benzo, sedative, or alcohol use		italoxone (rtarean		
☐ Active tapering chronic opioids			Yes 🗆 No	
☐ History of Overdose				
☐ Recent release from institution requiring abstinence				
CareOregon recommends all prior authorizations be submitted with supporting medical records to help for a				
faster and more thorough review				
Prescribers Signature:			Date:	